Warning: The NCBI web site requires JavaScript to function. more...
Is the combination of sulfonylureas and metformin associated with an increased risk of cardiovascular disease or all-cause mortality?: a meta-analysis of observational studies.
Rao AD, Kuhadiya N, Reynolds K, Fonseca VA.
Diabetes Care. 2008 Aug;31(8):1672-8. Epub 2008 May 5.PMID: 18458139 [PubMed - indexed for MEDLINE]Related articlesFree article
Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin.
Evans JM, Ogston SA, Emslie-Smith A, Morris AD.
Diabetologia. 2006 May;49(5):930-6. Epub 2006 Mar 9.PMID: 16525843 [PubMed - indexed for MEDLINE]Related articles
Antihyperglycemic treatment in diabetics with coronary disease: increased metformin-associated mortality over a 5-year follow-up.
Fisman EZ, Tenenbaum A, Benderly M, Goldbourt U, Behar S, Motro M.
Cardiology. 1999;91(3):195-202.PMID: 10516414 [PubMed - indexed for MEDLINE]Related articles
Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin.
Bowker SL, Majumdar SR, Veugelers P, Johnson JA.
Diabetes Care. 2006 Feb;29(2):254-8.PMID: 16443869 [PubMed - indexed for MEDLINE]Related articlesFree article
Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes.
Johnson JA, Majumdar SR, Simpson SH, Toth EL.
Diabetes Care. 2002 Dec;25(12):2244-8.PMID: 12453968 [PubMed - indexed for MEDLINE]Related articlesFree article
Reduced cardiovascular morbidity and mortality associated with metformin use in subjects with Type 2 diabetes.
Johnson JA, Simpson SH, Toth EL, Majumdar SR.
Diabet Med. 2005 Apr;22(4):497-502.PMID: 15787679 [PubMed - indexed for MEDLINE]Related articles
Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis.
Home PD, Pocock SJ, Beck-Nielsen H, Gomis R, Hanefeld M, Jones NP, Komajda M, McMurray JJ; RECORD Study Group.
N Engl J Med. 2007 Jul 5;357(1):28-38. Epub 2007 Jun 5.PMID: 17551159 [PubMed - indexed for MEDLINE]Related articlesFree article
Increased mortality in Type II diabetic patients using sulphonylurea and metformin in combination: a population-based observational study.
Olsson J, Lindberg G, Gottsäter M, Lindwall K, Sjöstrand A, Tisell A, Melander A.
Diabetologia. 2000 May;43(5):558-60.PMID: 10855529 [PubMed - indexed for MEDLINE]Related articles
The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis.
Pantalone KM, Kattan MW, Yu C, Wells BJ, Arrigain S, Jain A, Atreja A, Zimmerman RS.
Acta Diabetol. 2009 Jun;46(2):145-54. Epub 2009 Feb 5.PMID: 19194648 [PubMed - indexed for MEDLINE]Related articles
Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus.
Salpeter S, Greyber E, Pasternak G, Salpeter E.
Cochrane Database Syst Rev. 2003;(2):CD002967. Review. Update in: Cochrane Database Syst Rev. 2006;(1):CD002967. PMID: 12804446 [PubMed - indexed for MEDLINE]Related articles
Cochrane Database Syst Rev. 2002;(2):CD002967. Review. Update in: Cochrane Database Syst Rev. 2003;(2):CD002967. PMID: 12076461 [PubMed - indexed for MEDLINE]Related articles
Cochrane Database Syst Rev. 2006 Jan 25;(1):CD002967. Review.PMID: 16437448 [PubMed - indexed for MEDLINE]Related articles
Coronary heart disease outcomes in patients receiving antidiabetic agents.
McAfee AT, Koro C, Landon J, Ziyadeh N, Walker AM.
Pharmacoepidemiol Drug Saf. 2007 Jul;16(7):711-25.PMID: 17551989 [PubMed - indexed for MEDLINE]Related articles
Mortality in type 2 diabetic subjects prescribed metformin and sulphonylurea drugs in combination: cohort study.
Gulliford M, Latinovic R.
Diabetes Metab Res Rev. 2004 May-Jun;20(3):239-45.PMID: 15133756 [PubMed - indexed for MEDLINE]Related articles
Thiazolidinediones and cardiovascular events in patients with type 2 diabetes mellitus: a retrospective cohort study of over 473,000 patients using the National Health Insurance database in Taiwan.
Hsiao FY, Huang WF, Wen YW, Chen PF, Kuo KN, Tsai YW.
Drug Saf. 2009;32(8):675-90. doi: 10.2165/00002018-200932080-00006.PMID: 19591532 [PubMed - indexed for MEDLINE]Related articles
Effect of metformin treatment on multiple cardiovascular disease risk factors in patients with type 2 diabetes mellitus.
Abbasi F, Chu JW, McLaughlin T, Lamendola C, Leary ET, Reaven GM.
Metabolism. 2004 Feb;53(2):159-64.PMID: 14767866 [PubMed - indexed for MEDLINE]Related articles
Impact of oral antihyperglycemic therapy on all-cause mortality among patients with diabetes in the Veterans Health Administration.
Kahler KH, Rajan M, Rhoads GG, Safford MM, Demissie K, Lu SE, Pogach LM.
Diabetes Care. 2007 Jul;30(7):1689-93. Epub 2007 Apr 17.PMID: 17440170 [PubMed - indexed for MEDLINE]Related articlesFree article
Evaluation of adverse events of oral antihyperglycemic monotherapy experienced by a geriatric population in a real-world setting: a retrospective cohort analysis.
Asche CV, McAdam-Marx C, Shane-McWhorter L, Sheng X, Plauschinat CA.
Drugs Aging. 2008;25(7):611-22.PMID: 18582148 [PubMed - indexed for MEDLINE]Related articles
Comparison of extended-release metformin in combination with a sulfonylurea (glyburide) to sulfonylurea monotherapy in adult patients with type 2 diabetes: a multicenter, double-blind, randomized, controlled, phase III study.
Lewin A, Lipetz R, Wu J, Schwartz S.
Clin Ther. 2007 May;29(5):844-55.PMID: 17697903 [PubMed - indexed for MEDLINE]Related articles
Dose-response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort study.
Simpson SH, Majumdar SR, Tsuyuki RT, Eurich DT, Johnson JA.
CMAJ. 2006 Jan 17;174(2):169-74.PMID: 16415461 [PubMed - indexed for MEDLINE]Related articlesFree article
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on
» See more...